NCT00176813

Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer

Phase II Study of Gemcitabine, Cisplatin, and Celecoxib in the Treatment of Metastatic Pancreatic Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth. This is a phase II clinical trial studying the reactions of the patient's body and their tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur. Blood levels of celecoxib will be measured to find out how this treatment affects factors (proteins) involved in new blood vessel formation and tumor growth (angiogenesis).

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Gemcitabine
DRUG	Cisplatin
DRUG	Celecoxib

Timeline

• Start date: 2003-03-01
• Primary completion: 2003-11-01
• Completion: 2006-11-01
• First posted: 2005-09-15
• Last updated: 2008-05-06

Locations

1 site across 1 country: United States